AstraZeneca's COVID therapy becomes first antibody approved for immunocompromised people preexposure

People in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from the virus.

With the FDA’s emergency use authorization today of AstraZeneca’s long-acting antibody cocktail, the roughly 2% of U.S. residents who are immunocompromised will have a treatment that provides protection comparable to what healthy people receive from COVID-19 vaccines.